New drug described to alterlluridine treatment pathway
A recent article published in Nature Communications describes a new drug that may be able to prevent the conversion of lipid-acid-generating enzymes of the kidney to enzyme enzymes that break down immunosuppressive drugs.
‘The difficulty lies in identifying this compound, which might or might not work as intended,’ said Rezaab, who is a member of the Center for Pharmacodynamics and Therapeutics in the Department of Bioengineering and Biotechnology.
“Since Figueiredl4 is purified synthetically (conducted by a variety of synthetic chemical steps without toxic chemicals) it would be difficult to introduce it into the body without successful FDA approval.”